Drug Approval | October 02, 2024
Aurobindo Pharma receives USFDA approval for Cephalexin Tablets
The product is expected to be launched in Q3FY25
The product is expected to be launched in Q3FY25
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
2024 full-year revenue guidance raised by US$ 2 billion
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
Subscribe To Our Newsletter & Stay Updated
